Japan · Delayed Price · Currency is JPY Sumitomo Pharma Statistics
Total Valuation
Sumitomo Pharma has a market cap or net worth of JPY 565.68 billion. The enterprise value is 745.58 billion.
| Market Cap | 565.68B |
| Enterprise Value | 745.58B |
Important Dates
The next confirmed earnings date is Friday, July 31, 2026.
| Earnings Date | Jul 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Sumitomo Pharma has 448.59 million shares outstanding.
| Current Share Class | 448.59M |
| Shares Outstanding | 448.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 20.28% |
| Float | 238.43M |
Valuation Ratios
The trailing PE ratio is 4.69 and the forward PE ratio is 6.28.
| PE Ratio | 4.69 |
| Forward PE | 6.28 |
| PS Ratio | 1.25 |
| PB Ratio | 1.93 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 8.43 |
| P/OCF Ratio | 7.89 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.05, with an EV/FCF ratio of 11.11.
| EV / Earnings | 6.98 |
| EV / Sales | 1.64 |
| EV / EBITDA | 10.05 |
| EV / EBIT | 13.53 |
| EV / FCF | 11.11 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.77.
| Current Ratio | 1.03 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | 3.12 |
| Debt / FCF | 3.34 |
| Interest Coverage | 9.84 |
Financial Efficiency
Return on equity (ROE) is 46.27% and return on invested capital (ROIC) is 10.97%.
| Return on Equity (ROE) | 46.27% |
| Return on Assets (ROA) | 4.27% |
| Return on Invested Capital (ROIC) | 10.97% |
| Return on Capital Employed (ROCE) | 9.91% |
| Weighted Average Cost of Capital (WACC) | 5.46% |
| Revenue Per Employee | 118.29M |
| Profits Per Employee | 27.89M |
| Employee Count | 4,980 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 2.15 |
Taxes
| Income Tax | -6.52B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.51% in the last 52 weeks. The beta is 0.48, so Sumitomo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | +23.51% |
| 50-Day Moving Average | 1,492.55 |
| 200-Day Moving Average | 1,993.73 |
| Relative Strength Index (RSI) | 31.48 |
| Average Volume (20 Days) | 3,403,375 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sumitomo Pharma had revenue of JPY 453.29 billion and earned 106.87 billion in profits. Earnings per share was 268.99.
| Revenue | 453.29B |
| Gross Profit | 256.89B |
| Operating Income | 52.80B |
| Pretax Income | 100.34B |
| Net Income | 106.87B |
| EBITDA | 71.93B |
| EBIT | 52.80B |
| Earnings Per Share (EPS) | 268.99 |
Balance Sheet
The company has 44.31 billion in cash and 224.22 billion in debt, with a net cash position of -179.91 billion or -401.04 per share.
| Cash & Cash Equivalents | 44.31B |
| Total Debt | 224.22B |
| Net Cash | -179.91B |
| Net Cash Per Share | -401.04 |
| Equity (Book Value) | 292.47B |
| Book Value Per Share | 736.16 |
| Working Capital | 7.75B |
Cash Flow
In the last 12 months, operating cash flow was 71.72 billion and capital expenditures -4.61 billion, giving a free cash flow of 67.11 billion.
| Operating Cash Flow | 71.72B |
| Capital Expenditures | -4.61B |
| Depreciation & Amortization | 19.13B |
| Net Borrowing | -90.94B |
| Free Cash Flow | 67.11B |
| FCF Per Share | 149.59 |
Margins
Gross margin is 56.67%, with operating and profit margins of 11.65% and 23.58%.
| Gross Margin | 56.67% |
| Operating Margin | 11.65% |
| Pretax Margin | 22.14% |
| Profit Margin | 23.58% |
| EBITDA Margin | 15.87% |
| EBIT Margin | 11.65% |
| FCF Margin | 14.80% |
Dividends & Yields
Sumitomo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.00% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 18.89% |
| FCF Yield | 11.86% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Sumitomo Pharma is 2,128.57, which is 68.80% higher than the current price. The consensus rating is "Buy".
| Price Target | 2,128.57 |
| Price Target Difference | 68.80% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 11.17% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sumitomo Pharma has an Altman Z-Score of 1.83 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.83 |
| Piotroski F-Score | 5 |